Eli Lilly and Company $LLY Shares Bought by Courier Capital LLC

Courier Capital LLC raised its stake in shares of Eli Lilly and Company (NYSE:LLY) by 73.7% in the third quarter, HoldingsChannel reports. The institutional investor owned 8,112 shares of the company’s stock after purchasing an additional 3,443 shares during the period. Eli Lilly and Company accounts for about 1.8% of Courier Capital LLC’s holdings, making the stock its 12th biggest position. Courier Capital LLC’s holdings in Eli Lilly and Company were worth $9,386,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Catalyst Private Wealth LLC increased its stake in shares of Eli Lilly and Company by 4.5% in the third quarter. Catalyst Private Wealth LLC now owns 628 shares of the company’s stock worth $727,000 after acquiring an additional 27 shares during the last quarter. Lincoln Capital Corp raised its holdings in shares of Eli Lilly and Company by 21.4% during the third quarter. Lincoln Capital Corp now owns 255 shares of the company’s stock worth $295,000 after acquiring an additional 45 shares in the last quarter. Koesten Hirschmann & Crabtree INC. boosted its position in Eli Lilly and Company by 81.8% during the third quarter. Koesten Hirschmann & Crabtree INC. now owns 789 shares of the company’s stock valued at $913,000 after purchasing an additional 355 shares during the last quarter. Cascade Investment Group Inc. boosted its position in Eli Lilly and Company by 2.4% during the third quarter. Cascade Investment Group Inc. now owns 426 shares of the company’s stock valued at $493,000 after purchasing an additional 10 shares during the last quarter. Finally, First County Bank CT grew its stake in Eli Lilly and Company by 5.9% in the third quarter. First County Bank CT now owns 1,397 shares of the company’s stock valued at $1,616,000 after purchasing an additional 78 shares in the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Retatrutide is the key catalyst ahead of the Oct. 29 earnings report. Investors may focus less on the quarterly results than on progress for retatrutide, Lilly’s next-generation obesity candidate, which could potentially become a larger growth driver than Zepbound. Eli Lilly earnings and retatrutide article
• Positive Sentiment: Analysts see earnings upside. Erste Group raised its FY2026 EPS estimate to $36.55 from $36.45 and its FY2027 estimate to $47.30. RBC also reaffirmed an “Outperform” rating with a $1,500 price target, citing strong diabetes and weight-loss demand.
• Positive Sentiment: Lilly expanded its oncology pipeline. Prelude Therapeutics will test its experimental breast-cancer drug PRT13722 with Lilly’s Verzenio and Inluriyo, with Phase 1 enrollment expected to begin in the fourth quarter of 2026. The collaboration is early-stage but adds potential long-term pipeline value. Prelude and Lilly clinical trial collaboration
• Neutral Sentiment: Combination-treatment data were encouraging but mixed. Taltz plus Zepbound produced greater weight loss and improved psoriasis outcomes than standard treatment, while another obesity-drug combination generated more weight loss but also substantially higher discontinuation rates. Tolerability and patient persistence remain important commercial questions.
• Negative Sentiment: Valuation leaves limited room for disappointment. Lilly trades at a substantial premium to large pharmaceutical peers, so investors may be taking profits while awaiting earnings confirmation. Retatrutide’s clinical execution, pricing, and future pipeline success are increasingly important to justify the valuation.

Eli Lilly and Company Stock Down 1.3%

Eli Lilly and Company stock traded down $15.61 during mid-day trading on Tuesday, hitting $1,167.01. 1,843,111 shares of the company’s stock were exchanged, compared to its average volume of 2,952,320. The company has a current ratio of 1.35, a quick ratio of 1.00 and a debt-to-equity ratio of 1.41. The stock has a market cap of $1.10 trillion, a P/E ratio of 39.16, a P/E/G ratio of 1.47 and a beta of 0.46. Eli Lilly and Company has a 1-year low of $783.85 and a 1-year high of $1,292.65. The stock has a 50 day moving average of $1,175.57 and a two-hundred day moving average of $1,100.31.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, beating the consensus estimate of $6.40 by $1.98. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%. The company had revenue of $22.97 billion for the quarter, compared to analyst estimates of $20.82 billion. During the same period last year, the company earned $6.31 earnings per share. The business’s revenue was up 47.7% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, analysts anticipate that Eli Lilly and Company will post 36.19 EPS for the current fiscal year.

Insider Activity

In related news, CAO Donald A. Zakrowski sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the completion of the sale, the chief accounting officer directly owned 1,526 shares in the company, valued at approximately $1,808,325.26. The trade was a 56.72% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the business’s stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the completion of the sale, the executive vice president owned 11,875 shares of the company’s stock, valued at approximately $14,131,250. This trade represents a 29.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 13,500 shares of company stock valued at $15,958,170. Insiders own 0.14% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the company. Guggenheim upped their target price on Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the stock a “buy” rating in a research report on Friday, September 18th. Cantor Fitzgerald lifted their price target on Eli Lilly and Company from $1,410.00 to $1,440.00 and gave the company an “overweight” rating in a report on Thursday, October 8th. Citigroup boosted their price target on Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the company a “buy” rating in a research note on Wednesday, July 15th. The Goldman Sachs Group increased their price objective on Eli Lilly and Company from $1,367.00 to $1,371.00 and gave the stock a “buy” rating in a report on Thursday, September 17th. Finally, Sanford C. Bernstein increased their price objective on Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the stock an “outperform” rating in a report on Tuesday, July 14th. One research analyst has rated the stock with a Strong Buy rating, twenty-five have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Eli Lilly and Company has a consensus rating of “Moderate Buy” and an average price target of $1,313.43.

Eli Lilly and Company Profile

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer’s disease.